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Summary: Angiotensin converting enzyme (dipeptidyl carboxypeptidase, kininase II; EC 3.4.15.1), is a
membrane bound glycoprotein, playing an impqrtant role in the renin-aldosterone system. The enzyme
contains a carbohydrate moiety, consisting of fucose, mannose, galactose, N-acetylglucosamine and N-
acetylneuraminic acid. Treatment with nenraminidase (EC 3.2.1.18) removes sialic acid from the molecule.
The influence of this treatment on the electrophoretic mobility of the enzyme was studied in 29 human
tissues and body fluids. Results obtained showed differences in the sialic acid content of the enzyme in the
tissues examined.
Einfluß von Neuraminidase^Behandlung auf das elektrophoretische Verhalten von Angiotensin Converting Enzyme
aus menschlichen Geweben
Zusammenfassung: Angiotensin Converting Enzyme (Dipeptidyl carboxypeptidase, Kininase II; EC 3.4.15.1)
ist ein membrangebundenes Glykoprotein, das eine wichtige Rolle im Renin-Aldosteron-System spielt. Der
Kohlenhydratanteil enthält Fucose, Mannose, Galaktose, N-Acetylglucosamin und N-Acetylneuraminsäure.
Behandlung mit Neuraminidase (EC 3.2.1.18) spaltet Sialinsäure vom Molekül ab. Der Einfluß dieser
Behandlung auf die elektrophoretische Beweglichkeit des Enzyms wurde in 29 Geweben und Körperflüssigkei-
ten vom Menschen bestimmt. Die Ergebnisse weisen auf Unterschiede im Sialinsäuregehalt des Enzyms in
den untersuchten Geweben hin.
° -
üc ort
 ' tissue yielded lower catalytic activities. Several tissues
j Angiotensin converting enzyme (EC 3.4.15.1) or kini- from the digestive tract, in particular appendix and
' nase II is widely distributed in the body. In a previous ileum showed also a high converting enzyme activity.
i paper (1), we studied the electrophoretic behaviour
of converting enzyme inagar and polyacrylamide gel It has been shown by several authors, mostly in
electrophoresis in a variety of human tissue homoge- animal tissues, that angiotensin converting enzyme is
nates, and we found differences in electrophoretic a glycoprotein, with a rather important carbohydrate
mobility and extremely different enzyme catalytic ac- moiety. For instance the carbohydrate content of
tivities, dependingon the tissues studied. Surprisingly, converting enzyme from rabbit lung is estimated to
human benign prostatic hyperplasia showed the be 26% (2), composed of hexose, glucose, mannose,
highest angiotensin converting enzyme activity, galactose, N-acetylglucosamine and N-acetyl-neur-
whereas normal and adenocarcinomatous prostate aminic acid.
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Using agar gel electrophoresis, we studied the behav-
iour of converting enzyme in human tissue homoge-
nates before and after removal of sialic by treatment
with neuraminidase (EC 3.2.1.18).
Electrophoresis
Agar gel electrophoresis was carried out according to Wieme
(4). The methodology followed is deseribed in our previous
paper (1), together with the detectiori of the enzyme activity
(5)·
Materials and Methods
Reagents
Agar Noble was from Difco, Detroit, Mich., USA. Hippuricase
(EC 3.5.1.14) and the enzyme Substrate /?-hydroxyhippuryl-L-
His-L-Leu were obtained from Fujirebio, Tokyo, Japan.
Nonidet P 40 was from LKB, Bromma, Sweden.
Neuraminidase was purchased from Sigma, St. Louis, Missouri,
USA.
Octyl-ß-^-glucopyranoside was from Calbiochem-Behring, La
Jolla, California, USA.
Captopril (SQ 14225) was a generous gift from Squibb Belgium.
All other chemicals of high purity were obtained from Merck,
Darmstadt, FRG. In all assays deionized water was used.
Human tissues and body fluids
Biological fluids
Serum was obtained from blood bank donors, sperm from
healthy donors and prostatic fluid from vasectomized indivi-
duals. All fluids were chilled in liquid nitrogen and stored at
— 80 °C äs rapidly äs possible.
Tissues
The following were obtained by open surgery. Prostate (from
patients with prostatic carcinoma or benign prostatic hyperpla-
sia), normal prostate (from patients with bladder cancer), kid-
ney (cortex and medulla), xanthogranulomatous kidney, blad-
der, testis, ductus deferens, seminal vesicles, lung, sigmoid (nor-
mal and cancer), stomach (antrum and ulcus), spieen, ileum,
gall bladder, appendix, rectum, colon transversum, liver, thy-
roid, polynodular goitre, vena saphena magna, ovary, breast
cancer and bone marrow. The tissues were stored äs soon äs
possible in liquid nitrogen.
For each biological fluid or tissue, at least two specimens from
different patients were examined.
Tissue preparation
Tissues were homogenized by grinding in an Ehchjem glass
homogenizer with a teflon pestie, either by adding one drop
Nonidet P 40 per 200 mg tissue or according to the method of
Lazo & Quinn (3), using a 30 mmol/1 solution of octyl-ß-Z>-
glucopyranoside. After centrifugation at 50000g for 30 min at
4 °C in a MSE-cryofuge, the supernate was used for electropho-
resis, before and after neuraminidase treatment.
Neuraminidase treatment
Neuraminidase (3.4 mg, 2.5 units) was dissolved in 100 100
mmol/1 potassium phosphate buffer (pH 5.0). This solution (10
) was incubated for 5 h at 37 °C with an equal volume of
homogenate.
Results and Discussion
For the tissues and body fluids studied, we measured
the distance between the maxima of the major peak
before and after neuraminidase treatment. As shown
in our previous paper (1), agar gel electrophoresis
reveals multiple forms of the converting enzyme. In
this study we examined önly the mobility of the major
peak of the enzyme. Results are represented in figure
l. An example of the angiotensin converting enzyme
electrophoretic behaviour before and after neurami-
nidase treatment is represented for prostate (benign
hyperplasia) tissue homogenate in figure 2.
Longer treatment with neuraminidase had no effect
on the electrophoretic mobility of the major desialy-
lated enzyme peak. Koheü & Forstner (16) stated that
after two to three hours desialylation was complete.
In the last 5 tissues from figure l we found rjto
difference in electrophoretic behaviour before and
after neuraminidase treatment.
The number of sialic acid residues cleaved from the
converting enzyme molecule can only be calculated
when working on purified enzyme. As the tissues at
our disposal were obtained after open surgery, the
quantity available made an enzyme purification
impossible.
The method used gives very reprodücible results.
Treatment of 10 normal sera with neuraminidase
showed the same relative rnigration rate; the max-
imum enzymatic activities were all located in the same
slice of the agar gel cut in 10 slices between the
migration of albumin and the point with zero mobil··
ity. The presence of carbohydrate residues in convert-
ing enzyme was first demonstrated with a pure pre-
paration of converting enzyme from rabbit lung (7).
The authors found glucose, mannose, galactöse, N-
acetylglucosamine and N-acetylneuraminic acid. Osh*
ima et al. (8) showed that sialic acid can be removed
by neuraminidase without affecting the catalytic
properties of angiotensin cönverting enzyme. This
was later confirmed by Conroy et al. (9), studying
converting enzyme from canine lung which has a
carbohydrate content of 17%;fbut small amounts of
sialic acid.
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Fig. l. Change of electrophoretic mobility of angiotensin converting enzyme in agar gel after neuraminidase treatment is shown
for 29 human tissues. Results are expressed by measuring the difference of relative mobility of the major peaks before
and after neuraminidase treatment, and expressed äs the fraction of the distance between albumin and the zero point of
mobility taken arbitrarily äs 1.00. As can be seen from figure 2, taking the prostate enzyme äs an example, relative
mobility is 0.75 before and 0.35 after neuraminidase treatment. The difference in relative fractions is
0.75 - 0.35 .
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On the ordinate, the values can be read äs a function of the arbitrarily chosen relative mobility ränge (from 0 to l .00).
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Fig. 2. Electrophoretie pattern of angiotensin converting en-
zyme in prostate (benign hyperplasia) homogenate, be-
fore (o) and after neuraminidase treatment (o).
Abscissa: electrophoretic mobility in agar gel.
Ordinate: absorbance of the quinoneimine dye.
The most important difference in electrophoretic be-
haviour after neuraminidase treatment was found by
us iti angiotensin converting enzyme from human
serum, a fact which indicates the high content of sialic
acid in the cafböhydrate moiety of human serum
angiotensin converting enzyme. This is in agreement
with findings in several animäl species. Das et al. (10),
in a study on converting enzyme from rabbit lung
and serum stated that converting enzyme from serum
contains about tÜree times more sialic acid than con-
verting enzyme from lung. The authors suggested
that the sialic acid content may be necessary to keep
the converting enzyme of serum in the circulation
and prevent its removal by the liver. However, in
the guinea pig, the sugar moieties of angiotensin
converting enzyme in lung and serum are similar (11)
and the authors concluded that these findings lend
Support to the Suggestion that lung may possibly
serve äs a source for the serum enzyme. These find-
ings are exceptional, äs it is accepted (12) that many
of the galactosyl residues in the pulmonary enzyme
are probably exposed äs terminal non reducing units.
The generally high content of sialic acid relative to
galactose suggests that the serum enzyme contains
few such exposed galactosyl residues. Morelle et al.
(12) have observed that the serum survival time of a
number of plasma glycoproteins is markedly
shortened when their sialyl residues are removed. As
a result of desialylation, galactose is exposed äs a
terminal non-reducing residue and serves äs a specific
determinant for recognition of the sialic acid deficient
molecules by liver cells. A surface lectin capable of
binding to galactosyl-terminating glycoproteins has
been isolated from rabbit liver membrane (13).
Converting enzyme from hupian lung and kidney
differ in their sialic acid content (14). Lung contains
more acid forms, which confirms our findings.
It is not known why converting enzyme from benign
prostatic hyperplasia and prostatic cancer seem to
contain the same quantity of sialic acid. Yokoyama
et al. (15), in a histological study of benign prostatic
hyperplasia, stated that converting enzyme of benign
prostatic hyperplasia, whose biochemical properties
are very similar to those of human lung, is mainly
located in the cystic component, suggesting dilated
prostate acini may contain high converting enzyme
activity. In contrast, little enzyme activity was found
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in the stromal tissue. In fact, this means that the
glandular part of the prostate is the source of convert-
ing enzyme in the prostate, suggesting that in prostate
carcinoma this part of the gland is not influenced by
the cancer. Why the enzyme in normal prostate has
a lower content of sialic acid, can only be explained
by the hypothesis that dilated acini and lumen, which
are not present in normal tissue, cotild be the origin
of an angiotensin converting enzyme that is richer in
sialic acid.
Takada et al. (16) isolated converting enzyme from
human kidney and estimated the neutral sugar con-
tent to be 13% per weight. This valme is smaller than
those of enzyme in lung tissue, so that our results
corroborate these fmdings.
Complete explanation of our fmdings will require
further studies on the carbohydrate mpiety of angio-
tensin converting enzyme from these human tissues.
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